Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

NCT05779241 is registered in ClinicalTrials.gov with Lyndra Inc. as lead sponsor.

NCT NCT05779241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Lead sponsor
Lyndra Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 13, 2023
Completion date
December 1, 2023
Enrollment
83 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia